Tuesday, November 07, 2017 5:25:51 PM
For one, it is well established this is a new class antibiotic and is incredibly effective.
The liver issues are most likely overblown. I am not to high on Baxdela being launched and I doubt they will reach projected 400 mil in sales within 3 to 5 years but by the time Soli is approved they will have a seasoned sales force.
Within a year they will need more money, a couple hundred mil doesn’t last long when you launch a new drug.
There are other small catalysts that could help the news cycle but Soli is still the prize.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM